Skip to main content

25-02-2022 | ASCO GU 2022 | Conference coverage | Video

Neoadjuvant avelumab plus axitinib active in high-risk RCC

share
SHARE

Axel Bex outlines the reasoning behind the choice of tumor response as the primary endpoint for the NeoAvAx study of avelumab plus axitinib in the neoadjuvant high-risk renal cell carcinoma setting, and discusses the next steps (4:20).

Related content